WO2007133476A3 - Competitive substrate inhibition to increase drug bioavailability - Google Patents

Competitive substrate inhibition to increase drug bioavailability Download PDF

Info

Publication number
WO2007133476A3
WO2007133476A3 PCT/US2007/010806 US2007010806W WO2007133476A3 WO 2007133476 A3 WO2007133476 A3 WO 2007133476A3 US 2007010806 W US2007010806 W US 2007010806W WO 2007133476 A3 WO2007133476 A3 WO 2007133476A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug bioavailability
increase drug
substrate inhibition
competitive substrate
bioavailability
Prior art date
Application number
PCT/US2007/010806
Other languages
French (fr)
Other versions
WO2007133476A2 (en
Inventor
Eric Holmes
Original Assignee
Scolr Pharma Inc
Eric Holmes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scolr Pharma Inc, Eric Holmes filed Critical Scolr Pharma Inc
Publication of WO2007133476A2 publication Critical patent/WO2007133476A2/en
Publication of WO2007133476A3 publication Critical patent/WO2007133476A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention is directed to a method and a composition for improving the bioavailability of an orally administered drug having poor systemic bioavailability, by competitively inhibiting and retarding the metabolic inactivation of the drug.
PCT/US2007/010806 2006-05-08 2007-05-04 Competitive substrate inhibition to increase drug bioavailability WO2007133476A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79859206P 2006-05-08 2006-05-08
US60/798,592 2006-05-08

Publications (2)

Publication Number Publication Date
WO2007133476A2 WO2007133476A2 (en) 2007-11-22
WO2007133476A3 true WO2007133476A3 (en) 2007-12-27

Family

ID=38694398

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/010806 WO2007133476A2 (en) 2006-05-08 2007-05-04 Competitive substrate inhibition to increase drug bioavailability

Country Status (2)

Country Link
TW (1) TW200808353A (en)
WO (1) WO2007133476A2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102000078A (en) * 2010-10-25 2011-04-06 李一梅 Compound raloxifene hydrochloride tablets and preparation method thereof
CN108949946B (en) * 2017-05-25 2022-02-18 上海市预防医学研究院 UGT2 gene polymorphism site related to anti-tubercular drug hepatic injury and application thereof
CN111759820B (en) * 2020-08-24 2022-04-19 武汉人福药业有限责任公司 Oxcarbazepine tablet and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215462A1 (en) * 2001-12-21 2003-11-20 Wacher Vincent J. Use of UGT inhibitors to increase bioavailability

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030215462A1 (en) * 2001-12-21 2003-11-20 Wacher Vincent J. Use of UGT inhibitors to increase bioavailability

Also Published As

Publication number Publication date
WO2007133476A2 (en) 2007-11-22
TW200808353A (en) 2008-02-16

Similar Documents

Publication Publication Date Title
WO2009066326A3 (en) Improved process for the preparation of prasugrel and its pharmaceutically acceptable salts
WO2008067257A3 (en) Inhibitors of diacylglycerol o-acyltransferase type 1 enzyme
WO2010042163A3 (en) Quinoline compounds as inhibitors of angiogenesis, human methionine aminopeptidase, and sirt1, and methods of treating disorders
WO2007118185A3 (en) Inhibitors of the 11-beta-hydroxysteroid dehydrogenase type 1 enzyme
WO2009064388A3 (en) Inhibitors of human methionine aminopeptidase 1 and methods of treating disorders
WO2007117466A3 (en) Celastrol, gedunin, and derivatives thereof as hsp90 inhibitors
HUS1500030I1 (en) Method for enhancing the bioavailability of ospemifene
WO2007135527A3 (en) Benzimidazolyl compounds
WO2010136474A3 (en) Substituted aminobutyric derivatives as neprilysin inhibitors
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
WO2013053983A8 (en) Protein kinase inhibitors
WO2006049835A3 (en) Indole and benzimidazole derivatives
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2008033798A3 (en) A pyrrolopyrazin as syk-kinase inhibitor
RS50670B (en) Substituted quinoline derivatives as mitotic kinesin inhibitors
AU2007306104A1 (en) Hydrobenzamide derivatives as inhibitors of Hsp90
WO2008086122A3 (en) Imidazole derivatives as kinesin spindle protein inhibitors (eg-5)
UA97348C2 (en) HETEROCYCLIC NF-kB INHIBITORS
WO2008011117A3 (en) Antiviral protease inhibitors
WO2010130773A3 (en) Benzoxazolone derivatives as aldosterone symthase inhibitors
WO2008001201A3 (en) Pharmaceutical compositions of clopidogrel
WO2009051223A1 (en) Pharmaceutical composition for treatment of cataract
WO2007092157A9 (en) 7-(1h-imidazol-4-yl) methyl) -5,6,7,8-tetrahydroquinoline
WO2007133476A3 (en) Competitive substrate inhibition to increase drug bioavailability
WO2009041786A3 (en) Pharmaceutical composition comprising inhibitors of cell adhesion molecule isolated from piper longum for the prevention and treatment of inflammatory disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07776728

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07776728

Country of ref document: EP

Kind code of ref document: A2